Predictive Biosciences is a molecular diagnostics company headquartered in Lexington, MA. Launched in 2006 with a $10 million Series A financing, the company was jointly founded by leading healthcare investors, experienced entrepreneurs, and internationally-renowned scientists in the areas of tumor growth, tumor angiogenesis, and cancer markers. Predictive Biosciences possesses an extensive IP portfolio – including 18 issued and pending US patents – and deep in-house expertise in proteomics, diagnostics, oncology, and tumor biomarkers.
Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering novel diagnostic assays for informed cancer management™. Predictive seeks to significantly improve care and reduce healthcare costs for cancer patients by personalizing diagnostic workups and clinical interventions.
|10/01/08||Series B||21.75M||New Enterprise Associates, Kaiser Permanente Ventures||Unknown|